Viewing Study NCT06598527


Ignite Creation Date: 2025-12-25 @ 5:05 AM
Ignite Modification Date: 2026-03-02 @ 5:34 PM
Study NCT ID: NCT06598527
Status: RECRUITING
Last Update Posted: 2025-05-29
First Post: 2024-09-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
Sponsor: Yang Hong
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module